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ABSTRACT
The diseases involve heart and blood vessels are classified under cardiovascular diseases. Hypertension (HTN) is a disorder of the CV system 
characterized by elevated arterial blood pressure. Pulsatile drug delivery systems are on highlight today. This is due to their distinct advantage of 
releasing drug as the circadian rhythm of the disease. The beta-blockers are first-line therapy for the HTN. Hence, researches related to such modified 
formulations of these drugs are of need to increase the patient compliance and convenience. This review describes the various such systems published 
in literature. This also includes a brief description about circadian rhythm and beta-blockers. The researchers involved in the development of modified 
release formulations are the main target audience for this review.
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INTRODUCTION
Cardiovascular diseases (CVD) are the leading cause of death globally, 
representing ~30% of all mortality [1]. Hypertension (HTN), as the 
sole or comorbid component of a constellation of disorders of the CV 
system, is present in over 90% of all patients with CVD and affects 
nearly 74 million individuals in the United States [2].
HTN remains the leading cause of CV morbidity and mortality, 
including stroke, heart disease, kidney disease, and other vascular 
disease. The relationship between blood pressure (BP) and CV risk is 
linear, continuous, and additive to other well-known risk factors such 
as diabetes, dyslipidemia, obesity, and cigarette smoking [3]. In the 
majority of cases, HTN is thought to result from an interaction of genes 
with environmental factors [4].
HTN is a disorder of the CV system characterized by elevated 
arterial BP. The BP in the arteries is dependent on the energy of cardiac 
contractions, elasticity, and contractile state of arterial walls, as well 
as on the volume and viscosity of the blood. It fluctuates with every 
heartbeat [5].
The higher the BP elevation, the greater the likelihood that various 
CV complications will ensue. If untreated, about 50% of hypertensive 
patients die of coronary heart disease or congestive heart failure (HF), 
about 33% die of stroke, and 10–15% die of renal failure [6]. HTN is 
classified as essential (primary) or secondary to, for example, a renal 
parenchymal, renovascular or an endocrine disorder [7].
In industrialized countries, the risk of becoming hypertensive 
(BP >140/90 mmHg) during a lifetime exceeds 90%. Essential HTN 
usually clusters with other CV risk factors such as aging, being 
overweight, insulin resistance, diabetes, and hyperlipidemia. Most 
hypertensive patients need two or more drugs for blood-pressure 
control and concomitant statin treatment for risk factor reduction. 
Despite the availability of effective and safe antihypertensive drugs, 
HTN and its concomitant risk factors remain uncontrolled in most 
patients [8].
Circadian rhythms are defined as those rhythms that are 
endogenously generated, have a periodicity of approximately 24 h 
and whose rhythmicity persists when environmental conditions 
(light, temperature, posture, etc.) are kept constant [9]. In humans, 
many aspects of human physiology and behavior vary with circadian 
phase. Circadian rhythms are self-sustained and persist in the 
absence of environmental time cues with remarkable precision [10]. 
The biological clock drives all circadian rhythms in humans, whether 
relative to neurobehavioral function, hormones, physiology, or 
behavior [11].
The mammalian circadian system is organized in a hierarchy of 
oscillators. At the top of this hierarchy is the suprachiasmatic nucleus 
(SCN) of the anterior hypothalamus. The SCN is responsible for 
coordinating independent peripheral oscillators so that a coherent 
rhythm is orchestrated at the organismal level [12]. SCN is a cluster of 
nerve cells located in the brain region called the hypothalamus that is 
responsible for generating and coordinating circadian rhythmicity in 
mammals [13].
The SCN that are synchronized to solar time by direct retinal afferents. 
Individual SCN neurons are circadian clocks, their intrinsic oscillator 
consisting of a series of interlinked autoregulatory transcriptional/
post-translational feedback loops [14].
The humans exhibit circadian rhythms in hormone concentration 
(e.g., melatonin, varying between ~0 and 50 pM; cortisol, varying 
between ~100 and 400 nM), plasma lipid concentration, core body 
temperature, plasma glucose concentrations, heart rate, autonomic 
nervous system activity, BP, subjective alertness, and objective 
reaction time, independent of the sleep/wake, and fasting/feeding 
cycles [15].
CVD, diabetes, and obesity affect millions of people worldwide, and 
the rates of these cardiometabolic diseases are on the rise. Circadian 
misalignment results are as follows (Figs. 1 and 2):
•	 Impaired	glucose	tolerance	as	a	result	of	decreased	insulin	sensitivity	




Despite the recent and substantial advances in the treatment of HTN, the 
majority of patients still remains not optimally controlled; hence, the 
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need for innovative strategies to lower BP [17]. Traditional treatments, 
as well as many new approaches to HF, appear to have little impact on 
the risk of clinical progression or mortality [18].
β-blockers have been used widely since the 1970s in the treatment of 
HTN [19]. The use of beta-blockers (β-blockers) in clinical practice has 
been evolving for more than half a century. At present, these medications 
are used for a number of medical conditions such as unstable angina, 
acute myocardial infarction, HF, HTN, atrial fibrillation, ventricular 
arrhythmias, migraine headache, hyperthyroidism, essential tremor, 
aortic dissection, social phobia, glaucoma, esophageal varices, and so 
on [20].
In	humans,	at	least	three	types	of	beta-receptor	exist	(β1,	β2,	and	β3)	
and these are an integral part of the sympathetic nervous system. 
In	 the	 heart,	 β1-	 and	 β2-receptors	 are	 found	 in	 the	 sinoatrial	 and	
atrioventricular nodes and myocardium. Norepinephrine release from 
sympathetic nerve fibers stimulates beta-receptors causing heart 
rate and contractility to increase. Renin release from the kidney is 
also	mediated	 by	 β1-receptors,	 linking	 activation	 of	 the	 sympathetic	
nervous	 and	 renin-angiotensin	 systems.	 β2-receptors	 are	 found	 in	
the smooth muscle of venules and arterioles and stimulation of these 
receptors leads to vasodilatation [21].
Beta-blockers block the action of endogenous catecholamines on beta-
adrenergic	receptors.	There	are	 three	known	receptor	 types:	β-1,	2,	
and	3.	β-1	adrenergic	receptors	are	located	in	the	heart	and	kidneys;	
β-2	receptors	are	 in	 the	pancreas,	 liver,	 fat,	uterus,	vascular	smooth	
muscle,	and	skeletal	muscle;	and	β-3	receptors	are	 found	 in	 the	 fat.	
The non-selective drugs such as propranolol and labetolol, blocks 
all	 beta	 receptors.	 β-1	 selective	 agents,	 metoprolol,	 and	 bisoprolol	
act	 only	 on	 the	 heart.	 β-blockers	 act	 by	 decreasing	 heart	 rate	 and	
contractility, thereby balancing myocardial supply and demand 
and	 reduce	 cardiac	 events.	 β-blockers	 are	 also	 thought	 to	 stabilize	
coronary plaque, inhibit renin release, and increase the threshold for 
tachyarrhythmias [22].
Traditional	β-blockers	 -	propranolol,	atenolol,	metoprolol,	acebutolol,	
bisoprolol, betaxolol, penbutolol, nadolol, pindolol, and timolol are the 
most	 recommended	 and	 commonly	 used	 β-blockers	 for	 treatment	 of	
HTN.	Combined	α/β-blockers	such	as	carvedilol,	nebivolol,	and	labetalol	
can reduce BP by reducing systemic vascular resistance rather than 
by	decreasing	cardiac	output,	as	 is	observed	with	regular	β-blockers,	
yet not have the same vascular and metabolic effects as atenolol or 
metoprolol [23].
PULSATILE DRUG DELIVERY SYSTEMS
Oral pulsatile drug delivery systems are designed for application at 
the optimal time against diseases that occur depending on circadian 
rhythm. Most of the pulsatile drug delivery systems are reservoir 
systems with a barrier layer. The barrier can be dissolved or eroded 
after a predetermining lag time, and the drug is released outside from 
reservoir system [24].
With the advancement in medical science and understanding the 
importance of biodistribution and pharmacokinetics of therapeutic 
agents, modern drug delivery research strives to utilize novel materials 
and fabrication technologies for the preparation of robust drug delivery 
systems to combat acute and chronic diseases [25].
Pulsatile drug delivery systems are gaining a lot of interest in the field 
of modified release drug delivery systems. These systems constitute a 
relatively new class of devices, the importance of which is especially 
connected with the recent advances in chronopharmacology [26].
There are many conditions and diseases where sustained release 
formulations do not show good efficiency such conditions demand the 
release of drug after a lag time, i.e., form of pulse [27]. The pulsatile 
delivery system is also known as time controlled release system as it is 
independent of pH, enzymes, gastrointestinal motility, etc. [28].
Propranolol
Propranolol is a nonselective, competitive antagonist at beta-
adrenoceptors. It binds with high affinity to both beta-1 and beta-2 
receptor subtypes but has lower affinity at the beta-3 subtype. Although 
propranolol is rapidly absorbed following oral administration, it has a 
relatively low bioavailability due to significant first-pass metabolism. 
Propranolol is highly bound to plasma proteins and eliminated by 
hepatic metabolism [29].
Side effects of propranolol are rare but may include bradycardia, 
hypotension, and hypoglycemia. Other potential side effects 
include bronchospasm, fatigue, nightmares, HF, and peripheral 
vasoconstriction [30].
There are two pulsatile systems found in literature. The first one [31] 
is developed with minimization of transit time and pH effects of the 
gastrointestinal tract. The formulation compositions for matrix pellets 
prepared by an extrusion-spheronization method with the addition of 
either NaCl as osmogent and solubility modifier or lactose as osmogent 
using Eudragit (plasticized with 30% Triethyl citrate) as the controlling 
membrane.
The study by Newton et al. [32] has been designed to develop a 
delayed release matrix tablets using various natural polymers. The 
Carbopol 940 was used as an auxiliary polymer to modify the drug 
release and to improve the compression characteristics in high-speed 
tablet compression machines. The in vitro studies were performed 
in developed matrix system in 0.1 N HCl for 1.5-2 h and in pH 6.8 
phosphate buffer for 2 h and after that pH 7.4 buffer until the maximum 
amount of drug release.
Metoprolol
Metoprolol is a cardioselective beta-adrenoceptor antagonist. It has 
a	 higher	 affinity	 for	 β1-receptors	 than	 for	 the	 β2-receptor	 subtype.	
Receptor subtype selectivity is diminished at higher doses. Metoprolol 
and other beta-adrenoceptor antagonists are used widely to treat 
CVD, including HTN, angina, arrhythmias, myocardial infarction, and 
congestive HF [33].
A core in cup (three component tablet) is prepared wherein core 
tablet, an impermeable material surrounding the tablet except the top 
and soluble hydrophilic polymer layer at the top is designed. The core 
tablet contains metoprolol tartrate, cellulose acetate propionate is used 
as impermeable membrane and sodium alginate 500 cps and sodium 
Fig. 1: Circadian rhythm
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alginate 2000 cps used as a soluble hydrophilic polymer layer. The 
concentration of the top layer of hydrophilic polymer is a critical factor 
governing the release pattern, increase in the concentration increased 
lag time and delay the release [34].
Another pulsatile delivery system in which core tablets were prepared 
using various concentrations of super disintegrates, the formulated 
core tablets were coated with the polymers using compression coating 
technology. Three different formulations were prepared with varying 
concentrations of hydroxypropyl methylcellulose. The first formulation 
showed maximum drug release after 3 h and another two after the 
8th h [35].
In another study, a swellable tablet with Eudragit was prepared for the 
timed control release. To study the influence of the formulation factors 
(amount of coating polymer, plasticizer percentage in film coating, and 
swelling agent percentage in mini-tablets), a Box-Behnken design of 
experiment was used. The lag phase of 2.5-h followed by rapid drug 
release was obtained [36].
The study conducted by Emami and Kazemali [37] presented core 
tablets contained metoprolol, sodium chloride, lactose, Avicel, and 
starch. Powders were mixed, sieved, and directly compressed into 
tablets using a single punch tablet machine. Core tablets were then 
coated with 5 or 10% hydroxypropyl methylcellulose as a swelling layer 
and subsequently outer membrane with the mixture of various ratios of 
Eudragit at different coating levels 5, 10, and 15% as semi-permeable 
water insoluble outer coat by the conventional pan-spray method.
Another floating pulsatile delivery system consisted of three different 
parts: A core tablet, containing the active ingredient, an erodible outer 
shell, and a top cover buoyant layer. The rapid release core tablet (RRCT) 
was prepared using superdisintegrants along with active ingredient. 
Dry coating of optimized RRCT was done using different grades of 
hydroxypropyl methylcellulose (HPMC), and uppermost buoyant layer 
was prepared with HPMC and sodium bicarbonate. The optimized 
floating pulsatile release tablets (FPRT) formulation showed floating 
lag time of 4 min, floating time of 12 h and release lag time of 6 h [38].
Similarly, formulation consists of press-coated optimized RRCT 
were developed using different ratios of HPMC and Ethylcellulose. 
The swelling layer is composed of croscarmellose sodium, a super 
disintegrant and microcrystalline cellulose (MCC) as a diluent, while 
the rupturable coating is Ethylcellulose [39].
Fig. 2: Beta-blockers
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Pulsatile system with lag time of 6 h in onset of drug release in vitro 
followed by sustained drug release over a period of 12 h developed by 
Agrawal et al. [40]. Optimization of different grades of hydroxypropyl 
cellulose (HPC) polymer concentrations in the outer coat of tablets 
such that the optimized formulation contained low substituted HPC 
(L-HPC) and HPC-M in the ratio of 1:2. The optimized formulation 
produced a lag phase of 6 h followed by a complete release of 
99.02±0.82% in 12 h.
Taranalli et al. [41] developed hollow calcium pectinate beads 
for floating pulsatile release of metoprolol tartrate intended for 
chronopharmacotherapy. Floating pulsatile concept was applied to 
increase the gastric residence of the dosage form having lag phase 
followed by a burst release. The floating beads obtained were porous, 
float up to 12–24 h. All formulations followed first-order release 
kinetics by a diffusion mechanism.
Carvedilol
Carvedilol is a non-cardioselective beta-blocker used in the treatment 
of HTN and angina pectoris [42]. The addition of chronotherapy with 
carvedilol may be an effective way to suppress morning surges of 
HTN [43]. Carvedilol is a drug showing antioxidant properties used 
in clinical practice for the treatment of CVD (HTN, congestive HF, or 
myocardial infarction). The oral bioavailability remains low (e.g., 23%) 
due to significant first-pass hepatic metabolism by cytochrome P450 
and also has a short plasma half-life [44].
Compression coated tablet [45] containing carvedilol phosphate in the 
core was formulated with an outer coat by Eudragit and Ethylcellulose. 
A numerical optimization technique was adopted to achieve optimized 
formulation. The system was formulated into two steps: First, core 
tablet was prepared containing a drug; and second, core tablet was 
coated with a polymer blend of Eudragit (enteric polymer) and 
Ethylcellulose (water-insoluble polymer).
Rupturable pulsatile drug delivery system [46] consists of a drug 
core; swelling layer of a super disintegrant; and an insoluble, water 
permeable polymeric coating. On water ingress, the swellable layer 
expands, resulting in the rupturing of the outer membrane followed 
by drug release. The drug was deposited on sugar pellets as the first 
layer and the second layer composed of the swelling layer composed 
of swelling excipients, had crospovidone, HPC-L, and sodium starch 
glycollate. The outermost layer was composed of Ethylcellulose.
Core tablets (6 mm) containing carvedilol and 10-mm press-coated 
tablets were prepared [47] by direct compression using different 
concentrations of rate-controlling polymers. Hydroxypropyl 
methylcellulose, Ethylcellulose, and K-carrageenan were used as 
rate-controlling polymers in the outer layer. The varying lag time and 
percent cumulative carvedilol release after 8 h was optimized to obtain 
a formulation that offered a release profile with 6 h lag time followed by 
complete carvedilol release after 8 h.
Another chronotherapeutic delivery of carvedilol containing 
biodegradable polymers coated with pH sensitive polymers developed 
by Patel and Dhake [48]. Chitosan was used as a carrier for drug delivery, 
and Eudragit S100 was used as an enteric coating polymer. The chitosan 
microspheres were prepared by emulsion cross-linking method with an 
average particle size of microsphere formulations in the range of 9.93 
μm–18.48	μm.	Within	5	h	70–90%	of	the	drug	was	released.
Rupturable pulsatile mini-tablet consists of a drug core; swelling layer 
of a super disintegrant; an insoluble, water-permeable polymeric, and 
enteric coating. On water access, the swellable layer expands, resulting 
in the rupturing of the outer membrane followed by drug release. There 
was no drug released in the acid phase. The second layer composed 
of swelling excipient had crospovidone, croscarmellose sodium, and 
sodium starch glycolate. Third and the outer most layer was based on 
Ethylcellulose and an enteric polymer [49].
Bisoprolol
Bisoprolol fumarate possesses an asymmetric carbon atom in its 
structure and is provided as a racemic mixture [50]. Bisoprolol is the 
most	selective	among	the	other	second-generation	β-blockers	such	as	
metoprolol	and	atenolol	 [51].	The	β-blocker	bisoprolol	was	approved	
by the FDA as an antihypertensive agent for clinical use in 1992. The 
S(-)-enantiomer of bisoprolol possesses 15- to 40-times greater activity 
than the R(+)-enantiomer, thus, it is the most pharmacologically 
active [52].
Compression coated floating pulsatile drug delivery systems were 
developed by the Jagdale et al. [53] The prepared system consisted of 
two parts: A core tablet containing the active ingredient and an erodible 
outer shell with a gas generating agent. The inner core tablets were 
prepared by mixtures of bisoprolol fumarate, MCC, croscarmellose 
sodium, and lactose dry blended for 20 min followed by addition of 
magnesium stearate. FPRT were prepared by press coated method 
using polyethylene oxide. Sodium bicarbonate and citric acid were used 
as a gas generating agent.
Atenolol
Atenolol	is	a	β1-receptor	antagonist	that	is	widely	used	in	the	therapy	
of diverse CVD such as angina pectoris, cardiac arrhythmia, and 
systematic HTN [54]. In atenolol, the stereogenic center resides at 
the N-N-dimethyl propoxy side chain, resulting in the existence of 
enantiomeric pair. S-Atenolol is the S-enantiomer of (±)-atenolol, the 
eutomer,	which	 alone	 is	 responsible	 for	 the	 β-adrenoceptor	 blocking	
activity [55]. The S-enantiomer has been found to lack the reported 
side effect of a lowered heart rate sometimes encountered with the 
racemate [56].
Pulsatile release tablet comprises a drug containing core and 
pH-sensitive polymeric coating (Eudragit S-100, Ethylcellulose, 
and sodium alginate). In this system, MCC was used as the direct 
compressing agent. Crospovidone was used as disintegrating agents. 
Magnesium stearate and Talc were used as lubricants [57].
Another pulsatile formulation of atenolol was developed by Keraliya 
and Patel [58]. In this core, tablet consists of drug and coated with 
varying viscosity of HPC. With this two formulations with a lag phase 
of 6 and 6.5 h were prepared. The core tablet was prepared by mixing 
the drug with MCC, sodium starch glycollate, polyvinyl pyrrolidone 
(PVP), talc, and magnesium stearate. Followed by a coating of HPC 
was performed and formulation was optimized for the desired lag 
time.
The pulsatile delivery developed by Bonthagarala et al. [59] developed 
RRCT using superdisintegrants along with active ingredient atenolol. 
Press coating of optimized RRCT was done using different ratios of 
HPMC and Ethylcellulose. This system consists of a core tablet coated 
with two layers, an inner swelling layer and an outer rupturable 
coating. The swelling layer is composed of croscarmellose sodium, a 
super disintegrant and MCC as a diluent, while the rupturable coating 
is Ethylcellulose.
Another system Jagdale et al. [60] was generated which consisted of 
three different parts: A core tablet, containing the active ingredient; an 
erodible outer shell; and a top cover buoyant layer. The dry, coated tablet 
consists of a drug-containing core, coated by a hydrophilic erodible 
polymer responsible for a lag phase in the onset of pulsatile release. The 
buoyant layer, prepared with hydroxypropyl methylcellulose (HPMC), 
citric acid, and sodium bicarbonate, provides buoyancy to increase the 
retention of the oral dosage form in the stomach.
Nebivolol
Nebivolol	 is	 a	 third-generation	 β1-adrenoreceptor	 antagonist.	 Unlike	
other	drugs	in	the	same	type,	it	blocks	β1-adrenoreceptors	selectively.	
It is used a single daily dose. Nebivolol is metabolized in the liver and 
excreted through the kidneys [61].
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Nebivolol	 is	 a	 selective	 β1-blocker	 with	 a	 nitric	 oxide	 potentiating	
vasodilatory effect in comparison with other beta-blockers. Nebivolol 
has a direct stimulatory effect on endothelial nitric oxide synthase, 
which results in increased levels of local nitric oxide [62]. Nebivolol 
is used clinically for the treatment of HTN and chronic HF. The 
recommended dosage to relieve HTN is 5 mg/day as it shows the best 
cardioselectivity at such dosage [63]. The BP lowering effect is linked to 
a reduction in peripheral resistance and an increase in a stroke volume 
and preservation of cardiac volume [64].
Press coated pulsatile release tablets of nebivolol HCl developed by 
Nayak et al. [65] using an admixture of hydrophilic polymer, i.e., L-HPC 
and hydrophobic polymer, i.e., Ethylcellulose to achieve a predetermined 
lag time. The core tablet is prepared using superdisintegrants such 
as MCC and croscarmellose sodium. The press-coated pulsatile 
tablets containing nebivolol HCl in the inner core were prepared by 
compression coating with L-HPC and Ethylcellulose as the outer layer 
in different ratios.
Another system developed by Sandhya and Jagathi [66] using Ethylcellulose, 
xanthan gum, HPMC with lag phase of 6 h. The core tablet contains the 
drug and then coated with polymers such as xanthan gum, HPMC, and 
Ethylcellulose in varying proportions. After optimization, the selected 
formulation drug release was 99% at the end of 12 h. The core tablet was 
prepared using drug, Avicel, crospovidone, PVP, talc, and aerosol.
The system consisted of a core tablet coated with versatile and safe 
hydrophilic cellulosic ethers such as hydroxypropyl methylcellulose, 
HPC, and sodium carboxymethylcellulose was developed by Shivakumar 
et al. [67]. From the release profiles depicted in batch can be selected as 
optimized as it produced a lag time of 4.5 h with 96.51% drug release 
in 8 h.
FUTURE TRENDS
A total of 23 different pulsatile release formulations found in literature. 
They all are described in Table 1. These kind of formulations have a 
distinct advantage as compared to the conventional dosage form as 
the drug is released according to the circadian rhythm of the disease. 
Beta-blockers are first-line therapy for the HTN so the development of 
such modified release formulation will increase the patient compliance 
without any doubt. Such formulations also require skills during the 
development phase, and the major disadvantage is the limited dose 
can be incorporated due to the increase in mass due to polymers and 
other excipients. Thus, pulsatile release formulations of the drugs with 
high potency and lesser dose can be prepared. In the case of beta-
blockers, the bisoprolol is available in the form of 5 and 10 mg dosage 
formulations. This opens a new area of research for the research. Most 
of such formulations have been found for metoprolol, but the other 
beta-blockers such as atenolol and nebivolol also open the door for 
more research in this field.
CONCLUSION
Modern lifestyle factors are responsible for a growing burden of 
HTN: Physical inactivity, salt-rich diets with processed and fatty foods, 
and alcohol and tobacco use [68]. HTN can strain the heart, damage 
Table 1: Various developed pulsatile drug delivery systems of beta-blockers
Drug Lag time Technology References
Propranolol 5 h Using polymers: Ethylcellulose and Eudragit [31]
2 h Pectin was found to be most suitable compared with guar and xantham gum. [32]
Metoprolol 5 h Core in cup (three component tablets) [34]
Up to 8 h HPMC, Avicel PH-102, Starch pregelatinized, Aerosil 200, and Polyethylene glycol 400 [35]
2.5 h Coating with Eudragit [36]
5 h Core tablets contained the drug, sodium chloride, lactose, Avicel, and starch. Core tablets 
were then coated with 5 or 10% hydroxypropyl methylcellulose as a swelling layer and 
subsequently outer membrane with the mixture of various ratios of Eudragit.
[37]
6 h Three different parts: A core tablet, containing the active ingredient, an erodible outer shell, 
and a top cover buoyant layer.
[38]
96.3% release end 
of 8th h
The swelling layer is composed of croscarmellose sodium, MCC, the rupturable coating is an 
Ethylcellulose
[39]
6 h HPC polymer in the outer coat of tablets [40]
Slow release for 6 h 
then burst
Acid–base reaction during ionotropic cross-linking using low methoxy pectin, xanthan gum, 
sodium carboxymethyl cellulose, guar gum, locust bean, gellan gum, and calcium chloride as a 
cross-linking agent.
[41]
Carvedilol 8 h Ethylcellulose and Eudragit [45]
2.5 h First layer: Drug deposited on the sugar pellets
Second layer: Drug+Crosspovidone, HPC, and SSG
[46]
6 h Hydroxypropyl methylcellulose K4M, Ethylcellulose, and K-carrageenan were used as 
rate-controlling polymers in the outer layer.
[47]
70–90% of drug 
release within 5 h
Eudragit coated chitosan microspheres formulations (prepared by emulsion cross-linking 
method) in the range of 9.93 μm-18.48 μm
[48]
2 h Consists of a drug core, swelling layer, an insoluble, water-permeable polymeric, and enteric 
coating.
[49]
Bisoprolol 4 h Two parts: A core tablet containing the active ingredient and an erodible outer shell with a 
gas generating agent.
[53]
Atenolol 6 h By using pH-sensitive polymers (Eudragit S-100, Ethylcellulose, sodium alginate) [57]
6 and 6.5 h HPC polymer in the outer coat of tablets [58]
97.8% release with 
in 8 h
Two different parts: A core tablet, containing the active ingredient, an erodible. 




Three different parts: A core tablet, containing the active ingredient, an erodible outer shell, 
and a top cover buoyant layer.
[60]
Nebivolol 5.25 h Core tablet: Superdisintegrants like MCC, croscarmellose Na. Outer coating with 
hydroxypropyl cellulose and Ethocel.
[65]
6 h Coating with Ethylcellulose, xanthan gum, hydroxypropyl methylcellulose. [66]
4.5 h Effervescent agent in the core and coated with HPC [67]
HPMC: Hydroxypropyl methylcellulose, MCC: Microcrystalline cellulose, HPC: Hydroxypropyl cellulose
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blood vessels, and increase the risk of heart attack, stroke, kidney 
problems, and death [69]. Pulsatile drug delivery systems are gaining 
importance these days due to convenient and increase in patient 
compliance. They release of the drug is according to the circadian 
rhythm of the disease. Here, in this review, various such systems of beta-
blockers are discussed. This review is useful in the development of any 
such system irrespective of the disease for which it has been opt to. This 
review is also helpful for the researchers engaged in the development of 
modified release formulations particularly beta-blockers.
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